NCT00516724 2025-04-11
Study to Assess the Safety and Tolerability of a PARP Inhibitor in Combination With Carboplatin and/or Paclitaxel
AstraZeneca
Phase 1 Completed
AstraZeneca
Fudan University
Danish Breast Cancer Cooperative Group
Shanghai Jiao Tong University School of Medicine